Dr Bruck has a PhD in Biochemistry from University of Brussels. She was a post-doctoral student at Harvard University Medical School and an Assistant Professor at Tufts Medical School, before joining GlaxoSmithKline to build GSK’s HIV Vaccine Program. In her role in GSK’s Vaccine group, she was instrumental in the development of GSK’s HPV vaccine (Cervarix), and headed their cancer vaccine program from inception to phase 2, before joining the drug discovery group of GSK in King of Prussia, PA.
She held different roles in that group, from Head of Clinical Immunology (2004-2005) to VP and Head of Biology for the Center of Excellence for External Drug Discovery (2005-2008), to VP and Head of a newly formed Ophthalmology R&D group (2008-2015).
Currently, Dr Claudine Bruck is a Project Leader for BioMotiv. She also is co-founder and CEO of Prolifagen, a Start-Up company developing a microRNA based drug for tissue regeneration. She is also a course Director at University of Pennsylvania’s Institute of Translational Medicine and Applied Technology.